NICE nod for Velcade in stem cell transplant setting
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment body for England and Wales, has recommended use of Johnson & Johnson's proteasome inhibitor, Velcade (bortezomib), for use in patients newly diagnosed with multiple myeloma.